Financials Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-12-02 pm EST			5-day change	1st Jan Change
0.5886 ^USD	+2.92%		+2.56%	-46.00%

Nov. 14	Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q3 Revenue $3.8M	MT
Nov. 14	Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q3 Revenue $3.8M	MT

Projected Income Statement: Lineage Cell Therapeutics, Inc.

income-statement-evolution-chart LINEAGE-CELL-THERAPEUTICS

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	3.515	1.826	4.341	14.7	8.945	8.187	9.986	21.67
Change	-	-48.05%	137.73%	238.7%	-39.16%	-8.48%	21.98%	117.01%
EBITDA ¹	-35.75	-24.34	-48.34	-21.79	-24.04	-22.57	-27.65	-29.53
Change	-	-31.92%	98.63%	-54.92%	10.32%	6.12%	-22.51%	-6.8%
EBIT ¹	-38.88	-26.45	-49.21	-22.52	-24.73	-22.84	-25.56	-19.59
Change	-	-31.97%	86.07%	-54.24%	9.83%	7.65%	-11.92%	23.35%
Interest Paid	-	-1.039	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-19.23	-21.92	-43.27	-25.81	-23.28	-21.66	-21.43	-21.2
Change	-	13.99%	97.36%	-40.35%	-9.8%	6.95%	1.1%	1.05%
Net income ¹	-11.71	-20.65	-43.02	-26.27	-21.49	-21.66	-21.43	-21.2
Change	-	76.35%	108.33%	-38.93%	-18.22%	-0.81%	1.09%	1.05%
Announcement Date	3/12/20	3/11/21	3/10/22	3/9/23	3/7/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3
Net sales ¹	1.241	0.514	0.386	0.571	0.355	0.391	0.512	2.27	1.168	5.237	4.553	2.998	1.915	2.386	3.225	1.246	2.118	1.444	1.408	3.779	1.933	1.361	1.361	1.361	8.028	1.35	1.35	1.35
Change	-	-58.58%	-24.9%	47.93%	-37.83%	10.14%	30.95%	343.36%	-48.55%	348.37%	-13.06%	-34.15%	-36.12%	24.6%	35.16%	-61.36%	69.98%	-31.82%	-2.49%	168.39%	-48.85%	-29.59%	0%	0%	489.84%	-83.18%	0%	0%
EBITDA ¹	-6.068	-7.438	-5.858	-6.276	-5.521	-6.764	-6.883	-6.644	-28.05	-6.214	-4.055	-5.058	-6.466	-6.471	-4.854	-6.529	-6.187	-6.486	-5.725	-3.699	-6.66	-6.78	-6.89	-6.97	-7.01	-	-	-
Change	-	22.58%	-21.24%	7.14%	-12.03%	22.51%	1.76%	-3.47%	322.14%	-77.84%	-34.74%	24.73%	27.84%	0.08%	-24.99%	34.51%	-5.24%	4.83%	-11.73%	-35.39%	-80.05%	-1.8%	-1.62%	-1.16%	-0.57%	100%	-	-
EBIT ¹	-6.872	-7.438	-6.402	-6.725	-5.882	-7.05	-7.08	-6.843	-28.24	-6.396	-4.234	-5.251	-6.639	-6.642	-5.024	-6.705	-6.362	-6.661	-5.867	-3.84	-6.472	-7.084	-7.374	-7.539	1.796	-9.218	-9.718	-10.22
Change	-	8.24%	-13.93%	5.05%	-12.54%	19.86%	0.43%	-3.35%	312.66%	-77.35%	-33.8%	24.02%	26.43%	0.05%	-24.36%	33.46%	-5.12%	4.7%	-11.92%	-34.55%	-68.55%	-9.45%	-4.09%	-2.24%	-	-	-5.42%	-5.15%
Charge d'intérêts	-	-	-	-0.252	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-5.34	-8.428	-6.53	-7.95	0.984	-1.448	-4.965	-8.846	-28.01	-7.093	-6.782	-5.575	-6.362	-6.207	-5.203	-7.158	-4.714	-6.558	-5.773	-3.001	-6.403	-6.942	-7.26	-7.456	1.846	-9.218	-9.718	-10.22
Change	-	57.83%	-22.52%	21.75%	-	-	242.89%	78.17%	216.63%	-74.68%	-4.38%	-17.8%	14.12%	-2.44%	-16.18%	37.57%	-34.14%	39.12%	-11.97%	-48.02%	-113.36%	-8.41%	-4.59%	-2.71%	-	-	-5.42%	-5.15%
Net income ¹	-4.482	-8.399	-6.522	-7.76	2.032	-1.416	-4.788	-7.823	-28.99	-7.087	-6.763	-6.069	-6.354	-4.372	-5.229	-7.11	-4.775	-6.542	-5.76	-3.034	-6.418	-6.936	-7.254	-7.472	1.816	-9.218	-9.718	-10.22
Change	-	87.39%	-22.35%	18.98%	-	-	238.14%	63.39%	270.57%	-75.55%	-4.57%	-10.26%	4.7%	-31.19%	19.6%	35.97%	-32.84%	37.01%	-11.95%	-47.33%	-111.54%	-8.06%	-4.59%	-3.01%	-	-	-5.42%	-5.15%
Announcement Date	3/12/20	5/7/20	8/6/20	11/4/20	3/11/21	5/13/21	8/12/21	11/10/21	3/10/22	5/12/22	8/11/22	11/10/22	3/9/23	5/11/23	8/10/23	11/9/23	3/7/24	5/9/24	8/8/24	11/14/24	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 S1
Net sales ¹	0.9
Change	-
EBITDA ¹	-11.89
Change	-
EBIT	-
Change	-
Charge d'intérêts	-
Earnings before Tax (EBT) ¹	-14.96
Change	-
Net income ¹	-14.92
Change	-
Announcement Date	8/6/20

¹USD in Million

Estimates

Forecast Balance Sheet: Lineage Cell Therapeutics, Inc.

balance-sheet-analysis-chart LINEAGE-CELL-THERAPEUTICS

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	3/12/20	3/11/21	3/10/22	3/9/23	3/7/24	-	-	-

Estimates

Cash Flow Forecast: Lineage Cell Therapeutics, Inc.

Fiscal Period: December	2019	2022	2023	2024	2025	2026
CAPEX ¹	0.44	0.413	0.674	0.088	-	-
Change	-	-	63.2%	-86.94%	-100%	-
Free Cash Flow (FCF) ¹	-	0.646	-29.24	-24.23	-26.19	-14.76
Change	-	-	-4,626.32%	-17.13%	8.1%	-43.63%
Announcement Date	3/12/20	3/9/23	3/7/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Lineage Cell Therapeutics, Inc.

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-	-1,016.98%	-1,332.75%	-1,113.52%	-148.22%	-268.76%	-275.69%	-276.88%	-136.26%
EBIT Margin (%)	-	-1,106%	-1,448.36%	-1,133.63%	-153.17%	-276.5%	-279%	-255.99%	-90.41%
EBT Margin (%)	-	-547.2%	-1,200.66%	-996.77%	-175.56%	-260.28%	-264.61%	-214.55%	-97.83%
Net margin (%)	-	-333.12%	-1,130.83%	-990.99%	-178.69%	-240.2%	-264.58%	-214.55%	-97.83%
FCF margin (%)	-	-	-	-	4.39%	-326.89%	-295.98%	-262.3%	-68.13%
FCF / Net Income (%)	-	-	-	-	-2.46%	136.09%	111.87%	122.26%	69.64%
Profitability
ROA	-18.64%	-18.59%	-13.79%	-21.78%	-9.44%	-11.8%	-	-	-
ROE	-36.48%	-11.62%	-20.05%	-46.52%	-32.37%	-32.07%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	12.52%	-	-	2.81%	7.53%	1.07%	-	-
CAPEX / EBITDA (%)	-	-1.23%	-	-	-1.9%	-2.8%	-0.39%	-	-
CAPEX / FCF (%)	-	-	-	-	63.93%	-2.31%	-0.36%	-	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-0.08	-0.14	-0.26	-0.15	-0.12	-0.114	-0.1133	-0.106
Change	-	-	75%	85.71%	-42.31%	-20%	-5%	-0.59%	-6.47%
Nbr of stocks (in thousands)	-	149,794	149,991	168,558	169,976	174,987	220,416	220,416	220,416
Announcement Date	-	3/12/20	3/11/21	3/10/22	3/9/23	3/7/24	-	-	-